

# Giuseppe Saglio

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2896067/giuseppe-saglio-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

566  
papers

40,513  
citations

83  
h-index

192  
g-index

598  
ext. papers

44,727  
ext. citations

5.6  
avg, IF

6.43  
L-index

#	Paper	IF	Citations
566	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2408-17	59.2	2811
565	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 994-1004	59.2	2797
564	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 645-52	59.2	1693
563	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , <b>2013</b> , 122, 872-84	2.2	1413
562	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 254-66	59.2	1374
561	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 2251-9	59.2	1266
560	Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. <i>Leukemia</i> , <b>2003</b> , 17, 2318-57	10.7	1188
559	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6041-51	2.2	1019
558	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2006</b> , 108, 1809-20	2.2	998
557	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , <b>2006</b> , 108, 28-37	2.2	977
556	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. <i>Leukemia</i> , <b>1999</b> , 13, 1901-28	10.7	920
555	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. <i>Leukemia</i> , <b>2003</b> , 17, 2474-86	10.7	717
554	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. <i>Leukemia</i> , <b>2016</b> , 30, 1044-54	10.7	497
553	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2333-40	2.2	485
552	PML targeting eradicates quiescent leukaemia-initiating cells. <i>Nature</i> , <b>2008</b> , 453, 1072-8	50.4	455
551	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7374-9	12.9	405
550	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , <b>2011</b> , 118, 1208-15	2.2	395

549	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 841-51	21.7	383
548	European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 966-984	10.7	356
547	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , <b>2007</b> , 109, 3207-13	2.2	354
546	Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. <i>Blood</i> , <b>2007</b> , 88, 1011-21	2.2	348
545	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5195-201	2.2	337
544	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. <i>Leukemia</i> , <b>2012</b> , 26, 2197-203	10.7	335
543	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , <b>2014</b> , 123, 494-500	2.2	309
542	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1400-8	2.2	308
541	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , <b>2008</b> , 112, 3330-8	2.2	306
540	Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]. <i>Blood</i> , <b>1996</b> , 88, 2410-2414	2.2	305
539	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , <b>2011</b> , 117, 1141-5	2.2	296
538	Standardized definitions of molecular response in chronic myeloid leukemia. <i>Leukemia</i> , <b>2012</b> , 26, 2172-5	10.7	293
537	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , <b>2001</b> , 98, 3074-81	2.2	275
536	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , <b>2008</b> , 111, 1834-9	2.2	255
535	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4204-10	2.2	248
534	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5202-7	2.2	245
533	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. <i>Leukemia</i> , <b>2006</b> , 20, 1103-8	10.7	234
532	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RAR Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter AIDA Trial. <i>Blood</i> , <b>1998</b> , 92, 784-789	2.2	233

531	Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. <i>British Journal of Haematology</i> , <b>1988</b> , 69, 359-66	4.5	233
530	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 999-1003	10.7	229
529	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , <b>2014</b> , 123, 1353-60	2.2	196
528	Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. <i>Leukemia</i> , <b>2002</b> , 16, 2115-21	10.7	191
527	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. <i>European Journal of Haematology</i> , <b>2008</b> , 80, 168-76	3.8	183
526	Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. <i>Leukemia</i> , <b>2017</b> , 31, 1525-1531	10.7	180
525	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , <b>2009</b> , 114, 2159-67	2.2	180
524	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , <b>2007</b> , 92, 1173-9	6.6	177
523	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , <b>2009</b> , 114, 4933-8	2.2	176
522	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , <b>1996</b> , 94, 533-43	4.5	176
521	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , <b>1993</b> , 81, 166-176	2.2	174
520	Harmonization of molecular monitoring of CML therapy in Europe. <i>Leukemia</i> , <b>2009</b> , 23, 1957-63	10.7	170
519	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. <i>Leukemia</i> , <b>2013</b> , 27, 107-12	10.7	169
518	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRalpha-positive chronic eosinophilic leukemia. <i>Blood</i> , <b>2007</b> , 109, 4635-40	2.2	167
517	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. <i>Leukemia</i> , <b>2006</b> , 20, 1925-30	10.7	164
516	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , <b>2005</b> , 105, 3434-41	2.2	161
515	Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. <i>Leukemia</i> , <b>2013</b> , 27, 1310-5	10.7	160
514	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , <b>2009</b> , 113, 4497-504	2.2	158

513	Molecular pathways: BCR-ABL. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 930-7	12.9	156
512	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , <b>2007</b> , 92, 401-4	6.6	150
511	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , <b>2002</b> , 99, 1527-35	2.2	147
510	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , <b>2006</b> , 108, 1999-2005	2.2	146
509	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , <b>2014</b> , 123, 2317-24	2.2	137
508	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , <b>1993</b> , 81, 166-176	2.2	136
507	Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. <i>Blood</i> , <b>2000</b> , 95, 651-9	2.2	133
506	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , <b>1990</b> , 76, 1819-1824	2.2	126
505	Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1988-95	2.2	125
504	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , <b>2010</b> , 116, e1111-7	2.2	120
503	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 1205-13	5.5	109
502	Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. <i>Genomics</i> , <b>1997</b> , 42, 369-77	4.3	107
501	Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. <i>Haematologica</i> , <b>2010</b> , 95, 1308-16	6.6	103
500	Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75 (E 19) of the gamma chain. <i>Human Genetics</i> , <b>1976</b> , 32, 305-13	6.3	102
499	Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. <i>Blood</i> , <b>1996</b> , 87, 1075-1080	2.2	98
498	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 869-74	7.1	98
497	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <i>Cancer</i> , <b>2010</b> , 116, 3852-61	6.4	96
496	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , <b>2008</b> , 112, 3847-55	2.2	95

495	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , <b>2006</b> , 107, 473-9	2.2	93
494	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , <b>2015</b> , 125, 499-503	2.2	90
493	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. <i>Haematologica</i> , <b>2008</b> , 93, 921-4	6.6	90
492	Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. <i>Leukemia</i> , <b>2002</b> , 16, 1176-81	10.7	90
491	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 945-954	4.9	89
490	Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 896-904	1.9	88
489	Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. <i>Leukemia</i> , <b>2008</b> , 22, 96-102	10.7	87
488	Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. <i>Acta Haematologica</i> , <b>2008</b> , 120, 70-4	2.7	87
487	Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. <i>Cancer</i> , <b>2005</b> , 104, 101-9	6.4	86
486	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , <b>2012</b> , 120, 761-7	2.2	85
485	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 104, 4245-51	2.2	85
484	The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. <i>Leukemia</i> , <b>2006</b> , 20, 61-7	10.7	84
483	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , <b>2013</b> , 98, 193-200	6.6	83
482	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 1721-6	3.2	82
481	Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. <i>Genes Chromosomes and Cancer</i> , <b>1999</b> , 24, 16-23	5	81
480	WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. <i>Acta Haematologica</i> , <b>2004</b> , 112, 79-84	2.7	80
479	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. <i>Leukemia</i> , <b>2016</b> , 30, 57-64	10.7	78
478	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , <b>2011</b> , 117, 5591-9	2.2	78

477	Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4323-9	2.2	78
476	Monitoring treatment of chronic myeloid leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 161-9	6.6	78
475	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3037-42	12.9	78
474	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2005</b> , 19, 628-35	10.7	77
473	Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. <i>Annals of Oncology</i> , <b>1998</b> , 9, 55-61	10.3	77
472	Distribution of Kaposi's sarcoma herpesvirus sequences among lymphoid malignancies in Italy and Spain. <i>British Journal of Haematology</i> , <b>1995</b> , 91, 918-20	4.5	77
471	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 723-33	2.8	74
470	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , <b>2008</b> , 93, 1792-6	6.6	74
469	Nuclear factor kB as a target for new drug development in myeloid malignancies. <i>Haematologica</i> , <b>2007</b> , 92, 1224-9	6.6	74
468	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , <b>2013</b> , 121, 3703-8	2.2	73
467	c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. <i>International Journal of Cancer</i> , <b>1991</b> , 47, 833-8	7.5	73
466	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia.. <i>EMBO Journal</i> , <b>1984</b> , 3, 2641-2645	13	72
465	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , <b>2019</b> , 33, 1543-1556	10.7	70
464	AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. <i>American Journal of Clinical Pathology</i> , <b>1995</b> , 103, 561-7	1.9	70
463	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , <b>2015</b> , 125, 2771-8	2.2	68
462	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 2351-61	1.9	68
461	Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1982</b> , 79, 2347-51	11.5	68
460	What are RBC-transfusion-dependence and -independence?. <i>Leukemia Research</i> , <b>2011</b> , 35, 8-11	2.7	67

459	A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 9882-7	11.5	67
458	Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. <i>Aids</i> , <b>1996</b> , 10, 941-9	3.5	67
457	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , <b>2011</b> , 117, 6793-800	3.3	66
456	Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. <i>European Journal of Haematology</i> , <b>2009</b> , 82, 61-8	3.8	66
455	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 439-42	6.6	66
454	GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. <i>Blood</i> , <b>1998</b> , 91, 2334-2340	2.2	66
453	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162866	3.7	66
452	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , <b>2015</b> , 29, 1823-31	10.7	64
451	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. <i>Leukemia</i> , <b>2013</b> , 13, 1901-1928	10.7	62
450	Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , <b>2011</b> , 117, 1800-11	6.4	61
449	Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. <i>Cancer Genetics and Cytogenetics</i> , <b>1992</b> , 64, 170-3		61
448	G gamma and A gamma globin chains separation and quantitation by isoelectric focusing. <i>Biochemical and Biophysical Research Communications</i> , <b>1979</b> , 87, 1-8	3.4	61
447	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , <b>2016</b> , 101, 541-58	6.6	61
446	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 103, 2284-90	9.2	60
445	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. <i>Blood</i> , <b>2012</b> , 119, 5963-71	2.2	57
444	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , <b>2009</b> , 94, 205-12	6.6	54
443	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 484-7	4.5	54
442	Inhibition of c-myc expression induced by 4-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. <i>Biochemical and Biophysical Research Communications</i> , <b>1994</b> , 203, 553-61	3.4	54



441	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 59, 109-16	3.5	53
440	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , <b>2009</b> , 113, 3428-34	2.2	53
439	Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. <i>Blood</i> , <b>2010</b> , 115, 3382-9	2.2	53
438	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , <b>2000</b> , 14, 271-7	10.7	53
437	False-positive results with PCR to detect leukaemia-specific transcript. <i>Lancet, The</i> , <b>1990</b> , 335, 1037-8	4.0	53
436	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 797-805	7.1	52
435	Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, e51-2	2.2	52
434	Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. <i>Cancer</i> , <b>2002</b> , 94, 2416-25	6.4	52
433	BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. <i>Leukemia</i> , <b>2014</b> , 28, 1326-33	10.7	51
432	Human T gamma globin chain is a variant of A gamma chain (A gamma Sardinia). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1979</b> , 76, 3420-4	11.5	51
431	Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , <b>1995</b> , 91, 625-9	4.5	50
430	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. <i>Leukemia</i> , <b>2015</b> , 29, 1832-8	10.7	49
429	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , <b>2008</b> , 93, 770-4	6.6	49
428	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , <b>2007</b> , 92, 101-5	6.6	49
427	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , <b>2015</b> , 26, 185-192	10.3	48
426	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. <i>Haematologica</i> , <b>2012</b> , 97, 907-14	6.6	48
425	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2748-54	2.2	48
424	Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1674-83	12.9	46

423	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. <i>Blood</i> , <b>2006</b> , 107, 1591-8	2.2	44
422	BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. <i>American Journal of Pathology</i> , <b>1997</b> , 150, 155-65	5.8	44
421	BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- $\gamma$ in Chronic Myeloid Leukemia Patients. <i>Blood</i> , <b>1999</b> , 94, 2200-2207	2.2	43
420	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E66-72	7.1	42
419	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. <i>Blood</i> , <b>2011</b> , 118, 3634-3642	2.2	41
418	An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. <i>Haematologica</i> , <b>2007</b> , 92, 970-3	6.6	41
417	Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). <i>Blood</i> , <b>2014</b> , 124, 152-152	2.2	41
416	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. <i>Blood</i> , <b>2011</b> , 118, 5697-700	2.2	40
415	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 106-11	2.2	40
414	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. <i>Oncotarget</i> , <b>2017</b> , 8, 35508-35522	3.3	40
413	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia. <i>EMBO Journal</i> , <b>1984</b> , 3, 2641-5	13	40
412	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , <b>2016</b> , 30, 1844-52	10.7	40
411	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , <b>2019</b> , 3, 4280-4290	7.8	40
410	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , <b>2010</b> , 95, 1415-9	6.6	39
409	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , <b>2019</b> , 104, 1589-1596	6.6	38
408	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. <i>Haematologica</i> , <b>2014</b> , 99, 1204-11	6.6	38
407	Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. <i>Leukemia</i> , <b>2008</b> , 22, 1234-40	10.7	38
406	NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. <i>American Journal of Hematology</i> , <b>2006</b> , 81, 938-45	7.1	38

405	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 6034-6055	8.3	38
404	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , <b>2020</b> , 34, 2260-2261	10.7	37
403	Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. <i>Cancer Research</i> , <b>2007</b> , 67, 5300-7	10.1	37
402	Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. <i>Blood</i> , <b>1988</b> , 72, 1203-1208	2.2	37
401	Clinical and haematological data in 254 cases of beta-thalassaemia trait in Italy. <i>British Journal of Haematology</i> , <b>1976</b> , 33, 91-9	4.5	37
400	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , <b>2020</b> , 135, 534-541	2.2	37
399	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , <b>2021</b> , 35, 440-453	10.7	36
398	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , <b>2003</b> , 102, 2014-20	2.2	35
397	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , <b>1994</b> , 68, 3-7	3	35
396	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , <b>2016</b> , 122, 1398-407	6.4	35
395	Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , <b>2020</b> , 34, 1495-1502	10.7	34
394	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , <b>2008</b> , 93, 1814-21	6.6	34
393	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 454-9	2.2	34
392	4-hydroxynonenal specifically inhibits c-myc but does not affect c-fos expressions in HL-60 cells. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 227, 589-93	3.4	34
391	P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 1104-8	4.5	33
390	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. <i>Cancer</i> , <b>2006</b> , 106, 1188-96	6.4	33
389	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. <i>Leukemia</i> , <b>2002</b> , 16, 268-75	10.7	33
388	A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. <i>Blood</i> , <b>2000</b> , 95, 96-101	2.2	33

387	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. <i>Expert Review of Hematology</i> , <b>2010</b> , 3, 665-73	2.8	32
386	Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 24, 257-66		32
385	Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. <i>Blood</i> , <b>2003</b> , 102, 773-4; author reply 774	2.2	32
384	Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t(8;14) translocation. <i>Genes Chromosomes and Cancer</i> , <b>1993</b> , 8, 1-7	5	32
383	Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 287-99	5.4	31
382	Point mutations of the BCL-6 gene in Burkitt's lymphoma. <i>British Journal of Haematology</i> , <b>1997</b> , 99, 168-70		31
381	The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. <i>Leukemia</i> , <b>2000</b> , 14, 285-91	10.7	31
380	Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 9, 477-83	1.9	31
379	Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. <i>Leukemia</i> , <b>1993</b> , 7, 946-53	10.7	31
378	A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. <i>The Hematology Journal</i> , <b>2002</b> , 3, 315-6		31
377	Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. <i>Cancer</i> , <b>2004</b> , 101, 979-88	6.4	30
376	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>1996</b> , 16, 21-30	5	30
375	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , <b>2015</b> , 100, 1146-50	6.6	29
374	The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice. <i>Haematologica</i> , <b>2014</b> , 99, 1016-21	6.6	29
373	HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. <i>International Journal of Hematology</i> , <b>2009</b> , 90, 392-396	2.3	29
372	A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. <i>Journal of Chromatographic Science</i> , <b>2011</b> , 49, 753-7	1.4	29
371	Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. <i>American Journal of Hematology</i> , <b>1997</b> , 56, 206-13	7.1	29
370	JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , <b>2006</b> , 135, 267-8	4.5	29

369	Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. <i>Leukemia</i> , <b>2002</b> , 16, 1745-51	10.7	29
368	Analysis of microsatellite instability in chronic lymphoproliferative disorders. <i>Annals of Hematology</i> , <b>1996</b> , 72, 67-71	3	29
367	Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. <i>Leukemia</i> , <b>1992</b> , 6, 507-12	10.7	29
366	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. <i>Haematologica</i> , <b>2001</b> , 86, 252-9	6.6	29
365	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. <i>Hematological Oncology</i> , <b>2006</b> , 24, 196-204	1.3	28
364	A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2004</b> , 5, 50-5		28
363	Rapid identification by denaturing gradient gel electrophoresis of mutations in the gamma-globin gene promoters in non-deletion type HPFH. <i>British Journal of Haematology</i> , <b>1992</b> , 80, 533-8	4.5	28
362	Adherence to BCR-ABL inhibitors: issues for CML therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 223-9	2	27
361	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1059-63	12.9	27
360	The Role of PTEN in Myeloid Malignancies. <i>Hematology Reports</i> , <b>2015</b> , 7, 5844	0.9	26
359	Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. <i>Blood</i> , <b>2003</b> , 102, 2705-6	2.2	26
358	A new TaqI polymorphism in the p53 gene. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 928	20.1	26
357	Simultaneous screening for beta-thalassemia mutations by chemical cleavage of mismatch. <i>Genomics</i> , <b>1991</b> , 11, 48-53	4.3	26
356	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. <i>Blood</i> , <b>2013</b> , 122, 92-92	2.2	26
355	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , <b>2007</b> , 21, 1481-7	10.7	25
354	Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 14, 106-11	5	25
353	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. <i>Blood</i> , <b>1987</b> , 69, 1058-1061	2.2	25
352	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , <b>2014</b> , 38, 155-60	2.7	24

351	AIDS-related non-Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. <i>Acta Haematologica</i> , <b>1996</b> , 95, 193-8	2.7	24
350	Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. <i>Annals of Hematology</i> , <b>1994</b> , 69, 281-90	3	24
349	Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation. <i>American Journal of Human Genetics</i> , <b>1991</b> , 48, 631-5	11	24
348	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 398-407	4.5	23
347	5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 18	22.4	23
346	Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 1193-7	7	23
345	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph-negative peripheral stem cells. <i>British Journal of Haematology</i> , <b>1994</b> , 87, 867-70	4.5	23
344	A frequent A gamma-hereditary persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with beta-thalassemia. <i>Human Genetics</i> , <b>1988</b> , 79, 13-7	6.3	23
343	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , <b>1993</b> , 81, 166-76	2.2	23
342	Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. <i>Tissue Engineering - Part C: Methods</i> , <b>2017</b> , 23, 72-85	2.9	22
341	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <i>Leukemia Research</i> , <b>2014</b> , 38, 236-42	2.7	22
340	Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1401-12	3	22
339	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. <i>Leukemia</i> , <b>2013</b> , 27, 907-13	10.7	22
338	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , <b>2010</b> , 24, 66-73	10.7	22
337	Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	21
336	BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. <i>Cell Cycle</i> , <b>2015</b> , 14, 973-9	4.7	21
335	Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 143-9	4.5	21
334	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. <i>Leukemia</i> , <b>2007</b> , 21, 1442-50	10.7	21

333	HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. <i>Brain Pathology</i> , <b>1999</b> , 9, 199-208	6	21
332	A benign form of thalassaemia intermedia may be determined by the interaction of triplicated $\beta$ locus and heterozygous $\beta$ thalassaemia. <i>British Journal of Haematology</i> , <b>1987</b> , 66, 103-107	4.5	21
331	Delineation of specific beta-thalassaemia mutations in high-risk areas of Italy: a prerequisite for prenatal diagnosis. <i>Blood</i> , <b>1988</b> , 71, 983-988	2.2	21
330	The relationship between anemia, fecal stercobilinogen, erythrocyte survival, and globin synthesis in heterozygotes for beta-thalassaemia. <i>Blood</i> , <b>1975</b> , 46, 693-698	2.2	21
329	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , <b>2016</b> , 7, 80083-80090	3.3	21
328	The choice of first-line chronic myelogenous leukemia treatment. <i>Annals of Hematology</i> , <b>2015</b> , 94 Suppl 2, S123-31	3	20
327	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 345-50	3.5	20
326	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , <b>2006</b> , 17, 495-502	10.3	20
325	Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications. <i>Human Pathology</i> , <b>2000</b> , 31, 871-3	3.7	20
324	Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach. <i>British Journal of Haematology</i> , <b>1991</b> , 78, 286-8	4.5	20
323	A newly-characterized alpha-thalassaemia-1 deletion removes the entire alpha-like globin gene cluster in an Italian family. <i>British Journal of Haematology</i> , <b>1991</b> , 78, 529-34	4.5	20
322	The homozygous state for the -87 C---G beta + thalassaemia. <i>British Journal of Haematology</i> , <b>1990</b> , 75, 132-3	4.5	20
321	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. <i>Blood</i> , <b>2019</b> , 134, 2924-2924	2.2	20
320	Update on emerging treatments for chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 183-96	3.7	19
319	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , <b>2016</b> , 101, 1200-1207	6.6	19
318	Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 41, 86-91	5	19
317	Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continuous clinical remission. <i>British Journal of Haematology</i> , <b>1995</b> , 90, 364-8	4.5	19
316	Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population. <i>Breast Cancer Research and Treatment</i> , <b>1988</b> , 11, 147-53	4.4	19

315	ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7073-7073	2.2	19
314	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 131	22.4	19
313	Nilotinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , <b>2019</b> , 15, 953-965	3.6	19
312	Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2105-13	1.9	18
311	First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1523-1538	1.9	18
310	Two novel mutations in the tpmr6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 668-725	4.5	18
309	Abl: the prototype of oncogenic fusion proteins. <i>Cellular and Molecular Life Sciences</i> , <b>2004</b> , 61, 2897-911	10.3	18
308	The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 481-8	1.9	18
307	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>1993</b> , 84, 265-8	4.5	18
306	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Blood</i> , <b>1990</b> , 76, 1819-24	2.2	18
305	3' c-myc rearrangement in a human leukemic T-cell line. <i>Cancer Research</i> , <b>1986</b> , 46, 1413-7	10.1	18
304	The BCR-ABL/NF- $\kappa$ B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. <i>Oncotarget</i> , <b>2016</b> , 7, 66287-66298	3.3	18
303	IB- $\beta$ At the crossroad between oncogenic and tumor-suppressive signals. <i>Oncology Letters</i> , <b>2017</b> , 13, 531-534	2.6	17
302	Morgana acts as an oncosuppressor in chronic myeloid leukemia. <i>Blood</i> , <b>2015</b> , 125, 2245-53	2.2	17
301	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. <i>Blood Advances</i> , <b>2020</b> , 4, 2723-2735	7.8	17
300	Suboptimal responses in chronic myeloid leukemia: implications and management strategies. <i>Cancer</i> , <b>2012</b> , 118, 1181-91	6.4	17
299	BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 26, 281-6	1.9	17
298	Microsatellite instability in KSHV/HHV-8 positive body-cavity-based lymphoma. <i>Human Pathology</i> , <b>1997</b> , 28, 748-50	3.7	17



297	Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1028, 423-31	6.5	17
296	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. <i>Cancer Genetics and Cytogenetics</i> , <b>1989</b> , 42, 191-201		17
295	ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). <i>Blood</i> , <b>2010</b> , 116, 207-207	2.2	17
294	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. <i>Blood</i> , <b>2013</b> , 122, 653-653	2.2	17
293	Bone marrow microenvironment: The guardian of leukemia stem cells. <i>World Journal of Stem Cells</i> , <b>2019</b> , 11, 476-490	5.6	17
292	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , <b>2021</b> , 35, 1344-1355	10.7	17
291	NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. <i>PLoS ONE</i> , <b>2010</b> , 5, e12855	3.7	16
290	The molecular anatomy of the FIP1L1-PDGFR $\alpha$ fusion gene. <i>Leukemia</i> , <b>2009</b> , 23, 271-8	10.7	16
289	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 1017-24	6.6	16
288	Molecular defects associated with the acute phase CML. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11 Suppl 1, 25-8.	9	16
287	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , <b>2008</b> , 112, 181-181	2.2	16
286	Epha3 acts as proangiogenic factor in multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 34298-34309	3.3	16
285	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 644-6	4.5	16
284	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. <i>Haematologica</i> , <b>2003</b> , 88, 256-9	6.6	16
283	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , <b>2013</b> , 37, 520-30	2.7	15
282	Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 305-8	4.5	15
281	Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. <i>Journal of Oncology</i> , <b>2009</b> , 2009, 867380	4.5	15
280	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. <i>Leukemia Research</i> , <b>1996</b> , 20, 441-3	2.7	15

279	Haplotype distribution and molecular defects at the phenylalanine hydroxylase locus in Italy. <i>Human Genetics</i> , <b>1990</b> , 86, 69-72	6.3	15
278	Polymorphism of human gamma-globin genes in Mediterranean populations. <i>Nature</i> , <b>1979</b> , 282, 316-8	50.4	15
277	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. <i>Blood</i> , <b>2009</b> , 114, 1129-1129	2.2	15
276	Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. <i>Blood</i> , <b>2009</b> , 114, LBA-1-LBA-1	2.2	15
275	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , <b>2016</b> , 16, 572	4.8	15
274	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , <b>2018</b> , 97, 95-100	3	14
273	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 814-8	7.5	14
272	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. <i>Haematologica</i> , <b>2007</b> , 92, 1721-2	6.6	14
271	Lack of SH3 domain does not imply a more severe clinical course in Ph+ chronic myeloid leukemia patients. <i>Blood</i> , <b>2000</b> , 95, 4019-4020	2.2	14
270	p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR). <i>Leukemia and Lymphoma</i> , <b>1998</b> , 29, 595-605	1.9	14
269	Electrophoretic separation of A gamma and G gamma human globin chains in Nonidet P-40. <i>Clinica Chimica Acta</i> , <b>1979</b> , 99, 7-11	6.2	14
268	Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.. <i>Blood</i> , <b>2010</b> , 116, 3430-3430	2.2	14
267	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. <i>Blood</i> , <b>2012</b> , 120, 1675-1675	2.2	14
266	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes Irf3 mediated p53 nuclear exclusion. <i>Oncotarget</i> , <b>2015</b> , 6, 25217-25	3.3	14
265	Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 10978-10986	5.6	14
264	Dasatinib dose management for the treatment of chronic myeloid leukemia. <i>Cancer</i> , <b>2018</b> , 124, 1660-1672	7.4	13
263	Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 375-379	2	13
262	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. <i>BMC Cancer</i> , <b>2013</b> , 13, 173	4.8	13

261	BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. <i>PLoS ONE</i> , <b>2014</b> , 9, e110682	3.7	13
260	First-line therapy for chronic myeloid leukemia: new horizons and an update. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2010</b> , 10, 169-76	2	13
259	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 19, 250-255	5	13
258	Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. <i>Stem Cells</i> , <b>1993</b> , 11 Suppl 3, 67-72	5.8	13
257	Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , <b>2008</b> , 112, 450-450	2.2	13
256	Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia ChromosomePositive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , <b>2012</b> , 120, 1676-1676	2.2	13
255	Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse. <i>Scientific Reports</i> , <b>2016</b> , 6, 30725	4.9	13
254	A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. <i>Haematologica</i> , <b>1999</b> , 84, 707-15	6.6	13
253	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, 1530-1536	6.6	12
252	mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. <i>Haematologica</i> , <b>2019</b> , 104, 1789-1797	6.6	12
251	Milestones and monitoring. <i>Current Hematologic Malignancy Reports</i> , <b>2015</b> , 10, 167-72	4.4	12
250	Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical Transcripts. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	12
249	Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. <i>Scientific Reports</i> , <b>2016</b> , 6, 33432	4.9	12
248	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1303-1313	3	12
247	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , <b>2011</b> , 87, 409-18	3.8	12
246	Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 726-32	4.5	12
245	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 729-36	4.4	12
244	BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 31, 39-46	1.9	12

243	Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. <i>Medical and Pediatric Oncology</i> , <b>1991</b> , 19, 240-5		12
242	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , <b>2010</b> , 116, 359-359	2.2	12
241	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 767-773	3.5	11
240	Prospects for achieving treatment-free remission in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 318-327	4.5	11
239	CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. <i>Stem Cell Investigation</i> , <b>2017</b> , 4, 57	5.1	11
238	Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. <i>Leukemia Research</i> , <b>2018</b> , 67, 6-11	2.7	11
237	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2011</b> , 35, 504-7	2.7	11
236	CML: a model for targeted therapy. <i>Best Practice and Research in Clinical Haematology</i> , <b>2009</b> , 22, 285-94	4.2	11
235	Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16 Suppl, S96-S100	2	11
234	Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 88	7	11
233	HAUSP compartmentalization in chronic myeloid leukemia. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 318-21	3.8	10
232	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. <i>Leukemia</i> , <b>2020</b> , 34, 2064-2073	10.7	10
231	A comparative study of myocardial molecular phenotypes of two tfr2 <sup>hull</sup> mice: role in ischemia/reperfusion. <i>BioFactors</i> , <b>2015</b> , 41, 360-71	6.1	10
230	Molecular pathways in low grade B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 26 Suppl 1, 107-13	1.9	10
229	New therapeutic approaches and prognostic factors in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 625-8	1.9	10
228	CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF- $\kappa$ B subunit p65 at Ser536. <i>Leukemia</i> , <b>2007</b> , 21, 1305-6	10.7	10
227	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. <i>Neurological Sciences</i> , <b>2008</b> , 29, 185-7	3.5	10
226	Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?. <i>British Journal of Haematology</i> , <b>2006</b> , 135, 265-6	4.5	10

225	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. <i>Seminars in Hematology</i> , <b>2003</b> , 40, 37-41	4	10
224	ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. <i>British Journal of Haematology</i> , <b>1990</b> , 76, 39-44	4.5	10
223	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C--T nonsense mutation at codon 39.. <i>EMBO Journal</i> , <b>1984</b> , 3, 785-787	13	10
222	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). <i>Blood</i> , <b>2012</b> , 120, 1686-1686	2.2	10
221	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , <b>2012</b> , 120, 1686-1686	2.2	10
220	Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS7124-TPS7124	2.2	10
219	The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 88021-88033	3.3	10
218	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 617-22	7.1	10
217	Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2752-2754	1.9	9
216	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 410-2	3.2	9
215	Iron chelation therapy in myelodysplastic syndromes. <i>Advances in Hematology</i> , <b>2010</b> , 2010, 756289	1.5	9
214	Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?. <i>Seminars in Hematology</i> , <b>2010</b> , 47, 319-26	4	9
213	WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. <i>Methods in Molecular Medicine</i> , <b>2006</b> , 125, 199-211		9
212	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 27, 177-82	5	9
211	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. <i>Leukemia</i> , <b>1999</b> , 13, 1463-4	10.7	9
210	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. <i>Genes Chromosomes and Cancer</i> , <b>1996</b> , 15, 48-53	5	9
209	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , <b>2010</b> , 116, 2291-2291	2.2	9
208	Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. <i>Blood</i> , <b>2011</b> , 118, 2767-2767	2.2	9

207	Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , <b>2015</b> , 126, 2781-2781	2.2	9
206	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the United States. <i>Blood</i> , <b>2014</b> , 124, 2881-2881	2.2	9
205	Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 6501-6501	2.2	9
204	Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 6512-6512	2.2	9
203	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 1650-1657	5.6	9
202	A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
201	The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. <i>BMC Cancer</i> , <b>2016</b> , 16, 314	4.8	9
200	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1151-8	1.9	8
199	Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. <i>Acta Haematologica</i> , <b>2013</b> , 130, 268-78	2.7	8
198	Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias. <i>Advances in Hematology</i> , <b>2015</b> , 2015, 612567	1.5	8
197	Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. <i>European Journal of Haematology</i> , <b>1995</b> , 55, 184-8	3.8	8
196	Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?. <i>Blood</i> , <b>2005</b> , 105, 904; author reply 905	2.2	8
195	Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. <i>Blood</i> , <b>2005</b> , 106, 1887-8	2.2	8
194	Polymorphism of human fetal haemoglobin studied by isoelectric focusing. <i>FEBS Letters</i> , <b>1980</b> , 115, 68-70	2.8	8
193	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , <b>2008</b> , 112, 185-185	2.2	8
192	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. <i>Blood</i> , <b>2011</b> , 118, 452-452	2.2	8
191	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. <i>Oncoscience</i> , <b>2015</b> , 2, 382-94	0.8	8
190	Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. <i>Current Topics in Microbiology and Immunology</i> , <b>2000</b> , 252, 275-84	3.3	8

189	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
188	Ponatinib for chronic myeloid leukaemia: future perspectives. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 546-7	21.7	8
187	Glivec and CML: a lucky date. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2004</b> , 18, 246-51	0.7	8
186	Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , <b>2018</b> , 67, 67-74	2.7	7
185	Chronic myeloid leukemia: state of the art in 2012. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 379-86	6.3	7
184	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. <i>Cancer Letters</i> , <b>2009</b> , 276, 61-7	9.9	7
183	Practical monitoring of chronic myelogenous leukemia: when to change treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 121-9	7.3	7
182	From genes to therapy: the case of Philadelphia chromosome-positive leukemias. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 963, 306-12	6.5	7
181	Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1089, 411-23	6.5	7
180	Myelodysplastic syndromes. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1028, 400-8	6.5	7
179	Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. <i>Blood</i> , <b>2004</b> , 103, 2428; author reply 2429	2.2	7
178	MLL-AF6 fusion resulting from a new three-way translocation t(6;11;7) in a patient with acute myeloid leukemia. <i>Leukemia</i> , <b>2001</b> , 15, 1674-6	10.7	7
177	Translucis recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). <i>Leukemia</i> , <b>1999</b> , 13, 1635-7	10.7	7
176	Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor. <i>Stem Cells</i> , <b>1994</b> , 12, 521-6	5.8	7
175	Molecular characterization of Ph' + hybrid acute leukemia. <i>Leukemia Research</i> , <b>1989</b> , 13, 1061-7	2.7	7
174	Detection of Ph1-positive acute lymphoblastic leukaemia by PCR. GIMEMA Cooperative Study Group. <i>Lancet, The</i> , <b>1991</b> , 338, 958	40	7
173	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. <i>Blood</i> , <b>1987</b> , 69, 1058-61	2.2	7
172	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , <b>2011</b> , 118, 2756-2756	2.2	7

171	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , <b>2016</b> , 128, 3070-3070	2.2	7
170	Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. <i>Oncotarget</i> , <b>2016</b> , 7, 74082-74096	3.3	7
169	Mechanisms of p53 Functional De-Regulation: Role of the B-Myb-p53 Complex. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	7
168	The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. <i>Cancer Medicine</i> , <b>2016</b> , 5, 1650-3	4.8	7
167	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. <i>Blood Reviews</i> , <b>2017</b> , 31, 139-150	11.1	6
166	Highly Sensitive Detection of Mutations in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
165	Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis. <i>BioMed Research International</i> , <b>2017</b> , 2017, 2408941	3	6
164	Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 108-10	4.5	6
163	BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias. <i>Current Molecular Medicine</i> , <b>2012</b> , 12, 547-65	2.5	6
162	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 114-8	1.9	6
161	Involvement of the bcl-6 gene in AIDS-related lymphomas. <i>Annals of Oncology</i> , <b>1997</b> , 8, S105-S108	10.3	6
160	BCR/ABL rearrangement and leukemia phenotype. <i>Leukemia</i> , <b>1999</b> , 13 Suppl 1, S96	10.7	6
159	Immunoglobulin gene rearrangements in human multiple myeloma. <i>British Journal of Haematology</i> , <b>1989</b> , 73, 425	4.5	6
158	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>1991</b> , 52, 63-9		6
157	Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. <i>Leukemia Research</i> , <b>1982</b> , 6, 155-63	2.7	6
156	Fetal haemoglobin synthesis following fetal liver transplantation in man. <i>British Journal of Haematology</i> , <b>1983</b> , 55, 609-14	4.5	6
155	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , <b>2018</b> , 132, 44-44	2.2	6
154	Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib. <i>Blood</i> , <b>2010</b> , 116, 358-358	2.2	6



153	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. <i>Blood</i> , <b>2015</b> , 126, 4040-4040	2.2	6
152	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-]pyridine Scaffold: SAR of the Biphenyl Moiety. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 5404-5428	8.3	6
151	The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2000</b> , 110, 493-6	4.5	6
150	Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3330-3332	1.9	5
149	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , <b>2019</b> , 37, 240-252	1.3	5
148	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1938-48	1.9	5
147	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. <i>Oncotarget</i> , <b>2017</b> , 8, 6399-6405	3.5	5
146	Present results and future perspectives in optimizing chronic myeloid leukemia therapy. <i>Haematologica</i> , <b>2018</b> , 103, 928-930	6.6	5
145	RBC-transfusion guidelines update. <i>Leukemia Research</i> , <b>2012</b> , 36, 659-60	2.7	5
144	Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 491-495	4.5	5
143	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. <i>Biomarker Research</i> , <b>2015</b> , 3, 15	8	5
142	Repeated PCR in CML during IFN-alpha therapy. <i>European Journal of Haematology</i> , <b>1994</b> , 52, 152-5	3.8	5
141	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. <i>Blood</i> , <b>2009</b> ,	2.2	5
140	Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14). <i>Cancer Genetics and Cytogenetics</i> , <b>2007</b> , 173, 51-6		5
139	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. <i>Leukemia</i> , <b>2004</b> , 18, 1824-30	10.7	5
138	Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene. <i>Cancer Genetics and Cytogenetics</i> , <b>2002</b> , 132, 46-50		5
137	Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , <b>2002</b> , 133, 98-101		5
136	Soluble factor(s) released by the PF-382 T-cell line enhances the stimulatory effect of monocytes on the BFU-E growth. <i>Journal of Cellular Physiology</i> , <b>1988</b> , 135, 127-32	7	5

135	Meiotic recombination in the beta globin gene cluster causing an error in prenatal diagnosis of beta thalassaemia. <i>Journal of Medical Genetics</i> , <b>1988</b> , 25, 307-10	5.8	5
134	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7052-7052	2.2	5
133	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , <b>2021</b> , 196, 559	4.5	5
132	Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
131	Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. <i>Haematologica</i> , <b>2002</b> , 87, 688-94; discussion 694	6.6	5
130	Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. <i>Bioelectrochemistry</i> , <b>2018</b> , 122, 84-92	5.6	4
129	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , <b>2016</b> , 40, 24-9	2.7	4
128	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 181-9	7	4
127	Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13 Suppl 2, S272-5	2	4
126	Germ-line configuration of the T-cell receptor beta-chain gene in B-cell chronic lymphoproliferative disorders which co-express T-cell antigens. <i>European Journal of Haematology</i> , <b>1987</b> , 39, 412-7	3.8	4
125	Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 321-8	5	4
124	Identification of a novel mutation in the L ferritin iron-responsive element causing hereditary hyperferritinemia-cataract syndrome. <i>Acta Haematologica</i> , <b>2009</b> , 122, 223-5	2.7	4
123	Hematopoietic growth factors in autologous transplantation. <i>Biotherapy (Dordrecht, Netherlands)</i> , <b>1998</b> , 10, 299-308		4
122	Molecular characterization of hereditary persistence of fetal hemoglobin in a patient from Cuba [letter]. <i>Blood</i> , <b>1990</b> , 76, 1262-1263	2.2	4
121	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. <i>Cancer Genetics and Cytogenetics</i> , <b>1991</b> , 55, 235-41		4
120	Duplication of Ph and of 9q+ chromosomes during the blastic transformation of a CML case. <i>Cancer Genetics and Cytogenetics</i> , <b>1987</b> , 29, 57-63		4
119	Fetal diagnosis of beta-thalassaemia by DNA analysis in Italy. <i>Lancet, The</i> , <b>1986</b> , 1, 390	4.0	4
118	G gamma and a gamma globin chain synthesis in bone marrow and peripheral blood of beta-thalassaemia homozygotes. <i>British Journal of Haematology</i> , <b>1982</b> , 52, 225-31	4.5	4

117	Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern. <i>Blood</i> , <b>2018</b> , 132, 788-788	2.2	4
116	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. <i>Blood</i> , <b>2011</b> , 118, 3770-3770	2.2	4
115	The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program. <i>Blood</i> , <b>2014</b> , 124, 4534-4534	2.2	4
114	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C----T nonsense mutation at codon 39. <i>EMBO Journal</i> , <b>1984</b> , 3, 785-7	13	4
113	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 642005	5.3	4
112	A new BCR-ABL1 model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 717-728	6.6	4
111	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
110	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1852-5	4.7	3
109	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
108	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 188, e101-e105	4.5	3
107	Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 895-898	4.5	3
106	The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia. <i>Oncology Letters</i> , <b>2016</b> , 12, 3123-3126	2.6	3
105	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. <i>BMC Cancer</i> , <b>2013</b> , 13, 348	4.8	3
104	Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins. <i>Hybridoma</i> , <b>2011</b> , 30, 261-9		3
103	WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias. <i>Hematology</i> , <b>2005</b> , 10 Suppl 1, 76-8	2.2	3
102	Isochromosome 6p and deletion of 6q characterize two related cytogenetic clones in a patient with immunoblastic lymphoma. <i>Cancer Genetics and Cytogenetics</i> , <b>1995</b> , 81, 179-81		3
101	Haplotype distribution and molecular defects of PKU in Italy. <i>Journal of Inherited Metabolic Disease</i> , <b>1990</b> , 13, 292-4	5.4	3
100	Chromosome abnormalities involving heterochromatic regions in monocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>1990</b> , 46, 99-106		3

99	Genetic studies on some Nepalese populations. <i>Journal of Human Evolution</i> , <b>1979</b> , 8, 385-397	3.1	3
98	gamma chain composition in five Italian newborns heterozygous for Hb F Malta G gamma-117 His leads to Arg. <i>British Journal of Haematology</i> , <b>1980</b> , 44, 93-9	4.5	3
97	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , <b>2018</b> , 132, 1750-1750	2.2	3
96	Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. <i>Blood</i> , <b>2019</b> , 134, 2932-2932	2.2	3
95	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , <b>2009</b> , 114, 3292-3292	2.2	3
94	Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 6512-6512	2.2	3
93	Association of lymphocytosis following treatment with dasatinib with response and outcome.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 6553-6553	2.2	3
92	New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. <i>Oncoscience</i> , <b>2015</b> , 2, 880-91	0.8	3
91	Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia. <i>Current Drug Targets</i> , <b>2017</b> , 18, 389-395	3	3
90	BCR-ABL1 mutation [ponatinib resistance. <i>Blood</i> , <b>2016</b> , 127, 666-7	2.2	3
89	Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 22-23	4.5	3
88	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , <b>2020</b> , 38, 654-664	1.3	2
87	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1517-26	1.9	2
86	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. <i>Hematological Oncology</i> , <b>2018</b> , 36, 740-748	1.3	2
85	Emerging drugs for chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , <b>2010</b> , 15, 175-84	3.7	2
84	Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 1161-3	3.5	2
83	Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies. <i>Acta Haematologica</i> , <b>2008</b> , 120, 47-50	2.7	2
82	A young man with persistent eosinophilia. <i>Internal and Emergency Medicine</i> , <b>2007</b> , 2, 107-12	3.7	2

81	Thalidomide-induced partial stable remission in a case of refractory progressive B Cell Chronic Lymphoid Leukemia. <i>Leukemia Research</i> , <b>2008</b> , 32, 506-7	2.7	2
80	Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation. <i>Journal of Medical Genetics</i> , <b>1993</b> , 30, 228-31	5.8	2
79	Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia line. <i>Carcinogenesis</i> , <b>1992</b> , 13, 883-5	4.6	2
78	Recent advances in diagnosis of hemoglobinopathies. <i>Critical Reviews in Oncology/Hematology</i> , <b>1993</b> , 14, 89-105	7	2
77	Molecular evidence of transient complete remission after autografting in Ph-/bcr rearranged chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , <b>1989</b> , 72, 285-6	4.5	2
76	Molecular and cytogenetic studies of a patient with Philadelphia-negative, BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). <i>Genes Chromosomes and Cancer</i> , <b>1990</b> , 1, 284-8	5	2
75	A novel type of c-myc translocation in a T lymphoma cell line. <i>Annals of the New York Academy of Sciences</i> , <b>1987</b> , 511, 338-42	6.5	2
74	Cytogenetic and molecular analyses in Philadelphia chromosome positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>1988</b> , 69, 424-6	4.5	2
73	Composition of the $\epsilon$ -Chains of Human Fetal Hemoglobin at Birth and during Intrauterine Life. <i>Acta Haematologica</i> , <b>1979</b> , 62, 45-50	2.7	2
72	High Hb F levels in a Sardinian family: a genetic defect intermediate between HPFH Greek type and delta beta-thalassemia?. <i>Haematologica</i> , <b>1982</b> , 67, 499-507	6.6	2
71	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , <b>2018</b> , 132, 458-458	2.2	2
70	Molecular Heterogeneity of the FIP1L1-PDGFR $\alpha$ Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. <i>Blood</i> , <b>2004</b> , 104, 2428-2428	2.2	2
69	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , <b>2009</b> , 114, 2192-2192	2.2	2
68	Sequential Therapy with IMiD's in Relapsed-Refractory Multiple Myeloma Patients.. <i>Blood</i> , <b>2009</b> , 114, 2888-2888	2.2	2
67	Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 7054-7054	2.2	2
66	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6509-6509	2.2	2
65	Analysis of microsatellite instability in chronic lymphoproliferative disorders <b>1996</b> , 72, 67		2
64	Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2

63	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
62	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. <i>Haematologica</i> , <b>2021</b> , 106, 1787-1793	6.6	2
61	The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
60	Herpetic leg paralysis and abdominal ileus in a patient with idiopathic myelofibrosis. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 65-6	3.7	1
59	Second-generation TKIs: which and when?. <i>Leukemia Supplements</i> , <b>2012</b> , 1, S40-2	75	1
58	Minimal residual disease in B-lymphoproliferative disorders by PCR detection of immunoglobulin heavy chain gene recombination. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1997</b> , 57, 541-7	2	1
57	Recommendations for the Molecular Diagnosis of Familial Adenomatous Polyposis. <i>Tumori</i> , <b>1997</b> , 83, 795-799	1.7	1
56	Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma. <i>Acta Haematologica</i> , <b>2006</b> , 116, 70-1	2.7	1
55	Renal Hodgkin's disease. <i>British Journal of Haematology</i> , <b>2002</b> , 116, 732	4.5	1
54	Effect of IFN alpha therapy on secondary Ph1-positive clones. <i>British Journal of Haematology</i> , <b>1992</b> , 81, 451-3	4.5	1
53	Multilineage cell involvement in Ph1-negative, bcr-negative chronic myeloid leukemia. <i>Leukemia Research</i> , <b>1988</b> , 12, 637-45	2.7	1
52	Biosynthetic studies and gamma-chain composition in the Greek type of hereditary persistence of fetal hemoglobin and in its association with beta-thalassemia. <i>Acta Haematologica</i> , <b>1979</b> , 61, 272-7	2.7	1
51	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , <b>2018</b> , 132, 1732-1732	2.2	1
50	Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥5 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	1
49	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRα Rearrangement Can Be Effectively Treated with Imatinib. <i>Blood</i> , <b>2004</b> , 104, 1504-1504	2.2	1
48	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRα Rearrangement treated with Imatinib. <i>Blood</i> , <b>2004</b> , 104, 1507-1507	2.2	1
47	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML). <i>Blood</i> , <b>2005</b> , 106, 1096-1096	2.2	1
46	The Oncogenic Kinase Bcr-Abl Directly Regulates Splicing of BclX through a Quaternary Complex Coordinated by Nck-Beta and Sam-68 Adapter Proteins. <i>Blood</i> , <b>2009</b> , 114, 2171-2171	2.2	1

45	Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation. <i>Blood</i> , <b>2010</b> , 116, 2297-2297	2.2	1
44	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. <i>Blood</i> , <b>2012</b> , 120, 1702-1702	2.2	1
43	Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7055-7055 <sup>1</sup>	2.2	1
42	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , <b>2012</b> , 120, 4903-4903	2.2	1
41	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7054-7054	2.2	1
40	Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia. <i>Diseases (Basel, Switzerland)</i> , <b>2021</b> , 9,	4.4	1
39	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 739171	5.3	1
38	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
37	The biology of CML supports second-generation TKIs as frontline treatment. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 302-307	0.6	1
36	Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1564-5	1.9	0
35	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , <b>2021</b> , 35, 1814-1816	10.7	0
34	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 839915	5.3	0
33	Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes. <i>Annals of Hematology</i> , <b>2020</b> , 99, 891-893	3	
32	The Choice of First-Line Chronic Myelogenous Leukemia Treatment. <i>Hematologic Malignancies</i> , <b>2016</b> , 41-54	0	
31	Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 749-53	4.5	
30	Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , <b>2017</b> , 36, 149-156	1.9	
29	Development of cellular and humoral response against WT1 protein vaccination in mice. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E193-4	7.1	
28	Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. <i>Acta Haematologica</i> , <b>1997</b> , 97, 187-8	2.7	

- 27 Prognostic Significance of Molecular Follow-up by Qualitative and Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction in TEL/AML1 Positive Childhood Acute Lymphoblastic Leukemia. *Clinical Leukemia*, **2007**, 1, 298-303
- 26 Molecular monitoring in patients with chronic myelogenous leukemia. *Current Hematologic Malignancy Reports*, **2008**, 3, 65-71 4.4
- 25 Reply to Martinelli et al. *Leukemia*, **2003**, 17, 651-652 10.7
- 24 Novel type of BCR/ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. *British Journal of Haematology*, **2000**, 111, 644-646 4.5
- 23 Immunoglobulin DNA Analysis as a Marker of Clonality in the Follow-up of Patients with Hairy Cell Leukemia Treated with Alpha-Interferon. *Leukemia and Lymphoma*, **1990**, 2, 103-10 1.9
- 22 Significance of the Philadelphia chromosome in acute leukemias: variable correlation with rearrangements involving the c-abl and bcr genes. *Annals of the New York Academy of Sciences*, **1987**, 511, 270-6 6.5
- 21 7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. *Cytotechnology*, **1987**, 1, 37-40 2.2
- 20 Heterogeneity of delta, beta-thalassemia and hereditary persistence of Hb F in the Mediterranean area. *Annals of the New York Academy of Sciences*, **1985**, 445, 170-6 6.5
- 19 Analysis of the gamma chains in a homozygote for HPFH Negro type and in three related heterozygotes. *Acta Haematologica*, **1980**, 63, 146-50 2.7
- 18 Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. *Seminars in Hematology*, **2003**, 40, 37-41 4
- 17 Imatinib in the Treatment of CML Patients  $\geq 5$  Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. *Blood*, **2004**, 104, 2935-2935 2.2
- 16 Heterogeneous Chromosomal Mechanisms Generating the 5'RUNX1/3'CBFA2T1 Gene in Acute Myeloid Leukemia.. *Blood*, **2004**, 104, 4272-4272 2.2
- 15 Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. *Blood*, **2005**, 106, 1100-1100 2.2
- 14 JAK2V617F Mutation in Leukaemic Transformation of Philadelphia Negative Chronic Myeloproliferative Disorders.. *Blood*, **2006**, 108, 3605-3605 2.2
- 13 Bcr-Abl and Signal Transduction **2007**, 15-35
- 12 Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.. *Blood*, **2007**, 110, 1956-1956 2.2
- 11  $\beta$ -Thalassemic Syndromes As a Model for the Study of the Molecular Basis of Human Inherited Disease **1987**, 283-293
- 10 GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. *Blood*, **1998**, 91, 2334-2340 2.2



9	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. <i>Leukemia</i> ,13, 1463-1464	10.7
8	Recommendations for the Management of CML in the Era of Second-Generation TKIs <b>2016</b> , 131-145	
7	SIRT1 Activator 3 Potently Induces Apoptosis in Multiple Myeloma Cell Lines and in Primary Human Multiple Myeloma Cells.. <i>Blood</i> , <b>2009</b> , 114, 3845-3845	2.2
6	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. <i>Blood</i> , <b>2010</b> , 116, 2281-2281	2.2
5	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥5 years) Ph+ CML Patients [EudraCT Number 2007005102-42, ClinicalTrials.Gov NCT 00858806.. <i>Blood</i> , <b>2010</b> , 116, 3412-3412	2.2
4	Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.. <i>Blood</i> , <b>2012</b> , 120, 2500-2500	2.2
3	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. <i>Blood</i> , <b>2012</b> , 120, 1690-1690	2.2
2	Imatinib: The First-Line CML Therapy. <i>Hematologic Malignancies</i> , <b>2021</b> , 49-59	0
1	The best frontline therapy for CML: imatinib?. <i>Clinical Advances in Hematology and Oncology</i> , <b>2010</b> , 8, 240-2	0.6